Tonsillitis

Table of Contents

1. Overview
2. Epidemiology
3. Pathophysiology
4. Etiology and Risk Factors
5. Clinical Presentation
6. Diagnosis
7. Treatment
8. Complications
9. Prognosis
10. Prevention
11. Key Research Papers
12. Featured Videos

1. Overview

Tonsillitis is inflammation of the palatine tonsils — paired lymphoid organs located at the lateral walls of the oropharynx — most commonly caused by viral or bacterial infection. The tonsils form part of Waldeyer's tonsillar ring, a protective lymphoid collar that encircles the upper aerodigestive tract and constitutes the first organized immunological barrier against inhaled and ingested pathogens. When overwhelmed by infection, these tissues become acutely inflamed, enlarged, and painful, producing the characteristic syndrome of sore throat, dysphagia, fever, and cervical lymphadenopathy.

Tonsillitis is one of the most common conditions in primary care and pediatric medicine worldwide. In clinical practice it is often grouped under the broader term pharyngotonsillitis (or simply pharyngitis) when the pharyngeal mucosa is simultaneously involved, which is the norm. The etiological distinction between viral and bacterial tonsillitis is clinically important because Group A Streptococcus (GAS) — the dominant bacterial pathogen, responsible for approximately 40% of pharyngotonsillitis cases — requires antibiotic treatment to prevent serious non-suppurative complications including acute rheumatic fever and post-streptococcal glomerulonephritis. Viral causes account for the remaining ~60% of cases and do not benefit from antibiotics.

Tonsillitis is classified by temporal pattern:

• Acute tonsillitis — a single episode of rapid-onset tonsillar inflammation, typically lasting 7-10 days
• Recurrent acute tonsillitis — multiple distinct episodes per year separated by symptom-free intervals; the primary indication for tonsillectomy
• Chronic tonsillitis — persistent low-grade tonsillar inflammation with chronic sore throat, halitosis, and tonsillar crypts filled with caseous debris (tonsilloliths); less common and sometimes controversial as an entity

Management spans from watchful waiting and symptomatic care in uncomplicated viral cases to targeted antibiotic therapy for GAS, and surgical tonsillectomy for recurrent or obstructive disease. Understanding the diagnostic criteria, antibiotic stewardship principles, and surgical indications is essential for optimal care.

Back to Table of Contents

2. Epidemiology

Tonsillitis and pharyngitis together account for approximately 15 million physician office visits per year in the United States. The condition is most prevalent in school-age children, with the peak incidence between 5 and 15 years of age. GAS pharyngotonsillitis is responsible for 15-30% of pharyngitis cases in children and 5-15% in adults presenting to clinical settings. Adults generally have lower rates of streptococcal infection, partly because of accumulated immunity after repeated childhood exposures.

Globally, GAS infections remain a major public health burden. The World Health Organization estimates that GAS causes over 600 million cases of pharyngitis annually worldwide. The burden of disease is disproportionately high in low- and middle-income countries, where inadequate access to antibiotics and healthcare allows uncomplicated GAS pharyngitis to progress to acute rheumatic fever (ARF) and ultimately rheumatic heart disease (RHD), a major cause of cardiovascular morbidity and death in young people in sub-Saharan Africa, Southeast Asia, and the Pacific.

In the United States, ARF has become uncommon (incidence <0.5 per 100,000 per year) due to widespread antibiotic access and improving socioeconomic conditions. However, outbreaks of virulent GAS strains capable of causing ARF still occur episodically. Tonsillectomy is one of the most frequently performed surgical procedures in the United States, with approximately 530,000 procedures per year in children under 15. The annual cost of tonsillitis-related care exceeds $700 million in the US alone.

Seasonality is notable: GAS pharyngotonsillitis peaks in late winter and spring (January through May in the Northern Hemisphere) and is transmitted by respiratory droplets and direct contact with infected secretions. Crowded environments — schools, daycare centers, military barracks — facilitate spread. The incubation period is 2-5 days.

Back to Table of Contents

3. Pathophysiology

Tonsillar Immunology

The palatine tonsils are specialized secondary lymphoid organs covered by a stratified squamous epithelium that invaginates to form deep crypts, dramatically increasing the surface area available for antigen sampling. The tonsillar crypts trap inhaled and ingested antigens and microorganisms, which are then processed by the underlying lymphoid tissue containing germinal centers with B lymphocytes, T cell zones with helper and cytotoxic T cells, macrophages, and dendritic cells. This architecture makes the tonsils highly efficient at initiating both humoral and cell-mediated immune responses against mucosal pathogens.

Viral Tonsillitis

Viral pathogens — most commonly adenovirus, rhinovirus, coronavirus, Epstein-Barr virus (EBV), cytomegalovirus (CMV), and herpes simplex virus (HSV) — infect tonsillar epithelial and lymphoid cells directly, triggering innate immune responses. Pattern recognition receptors (Toll-like receptors, RIG-I) detect viral nucleic acids and activate NF-κB and interferon regulatory factor pathways, inducing production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and type I interferons. The resulting tissue inflammation causes vascular dilation, edema, neutrophil infiltration, and the characteristic erythema and swelling of the tonsils. EBV, which infects B lymphocytes via the CD21 receptor, causes marked lymphocyte proliferation and the extensive tonsillar and systemic lymphadenopathy that characterizes infectious mononucleosis.

Bacterial Tonsillitis (GAS)

Streptococcus pyogenes (Group A Streptococcus) is the most clinically important bacterial cause of tonsillitis. GAS colonizes the pharyngeal mucosa using a surface protein called M protein, which is the dominant virulence factor and provides resistance to phagocytosis by inhibiting complement deposition. GAS produces numerous toxins and enzymes that facilitate tissue invasion and immune evasion:

• Streptolysins S and O — membrane-damaging toxins that lyse red blood cells, leukocytes, and platelets; streptolysin O triggers anti-streptolysin O (ASO) antibodies used diagnostically
• Streptococcal pyrogenic exotoxins (SPE A, B, C) — superantigens that bypass normal antigen processing and directly activate up to 20% of T cells simultaneously, driving massive cytokine release; responsible for the scarlet fever rash and streptococcal toxic shock syndrome
• DNases (streptodornase), hyaluronidase, streptokinase — facilitate spread through tissue planes
• C5a peptidase — cleaves complement component C5a, impairing neutrophil chemotaxis

The inflammatory response to GAS produces intense tonsillar edema and exudate formation. A critical pathophysiological mechanism involves molecular mimicry: antibodies produced against the GAS M protein cross-react with human cardiac proteins (myosin, tropomyosin, laminin) in genetically susceptible individuals, causing the carditis of acute rheumatic fever. This explains why complete eradication of GAS with a full antibiotic course — even in mild or resolving cases — is essential to prevent rheumatic fever.

Back to Table of Contents

4. Etiology and Risk Factors

Viral Causes (~60% of cases)

• Adenovirus — most common viral cause of pharyngotonsillitis; typically causes concurrent conjunctivitis (pharyngoconjunctival fever), cough, and rhinitis; serotypes 1, 2, 3, 5, and 7 most implicated
• Rhinovirus and coronavirus — common cold viruses; pharyngitis tends to be mild
• Epstein-Barr virus (EBV) — causes infectious mononucleosis; presents with severe exudative tonsillitis, marked bilateral cervical lymphadenopathy, splenomegaly, and atypical lymphocytosis; ampicillin or amoxicillin causes a diffuse maculopapular rash in EBV-infected patients and must be avoided
• Cytomegalovirus (CMV) — mononucleosis-like syndrome, especially in immunocompromised patients
• Herpes simplex virus (HSV-1) — primary herpetic pharyngotonsillitis with vesicles and ulcers; more common in adolescents and young adults
• Influenza A and B — pharyngitis as part of systemic influenza syndrome
• Parainfluenza virus — mild-to-moderate pharyngitis, croup in children
• Enterovirus (Coxsackievirus A) — herpangina; vesicles on soft palate and anterior tonsillar pillars; associated with hand-foot-mouth disease

Bacterial Causes (~40% of cases)

• Group A Streptococcus (Streptococcus pyogenes) — the dominant bacterial pathogen; responsible for 30-40% of pharyngotonsillitis in children and 5-15% in adults presenting clinically; the only common cause requiring routine antibiotic treatment to prevent rheumatic fever
• Group C and G Streptococcus — cause pharyngotonsillitis similar to GAS but do not cause rheumatic fever; epidemiologically linked to foodborne outbreaks
• Fusobacterium necrophorum — emerging pathogen in adolescents and young adults with recurrent or exudative tonsillitis; associated with Lemierre's syndrome (jugular vein septic thrombophlebitis and septic emboli)
• Mycoplasma pneumoniae — typically causes tracheobronchitis but can cause pharyngitis; responds to macrolides
• Chlamydophila pneumoniae — uncommon cause of pharyngitis; associated with hoarseness
• Neisseria gonorrhoeae — pharyngeal gonorrhea in sexually active adolescents and adults; often asymptomatic
• Corynebacterium diphtheriae — historically important; produces a classic grayish-white pseudomembrane; now rare due to vaccination
• Vincent's angina — mixed anaerobic infection (Fusobacterium and spirochetes) causing ulcerative tonsillitis in immunocompromised or malnourished patients

Risk Factors

• Young age — children 5-15 years have the highest GAS attack rates; tonsil size is largest in childhood and involutes after puberty
• Close contact and crowding — schools, daycare, dormitories, military housing
• Immunosuppression — HIV, corticosteroid therapy, chemotherapy, transplant immunosuppression
• Previous tonsillitis episodes — recurrent disease predicts further recurrence
• Seasonal factors — GAS incidence peaks in winter and spring
• Tobacco smoke exposure — both active and passive smoking impair mucosal immunity
• Allergic rhinitis and postnasal drip — promote pharyngeal mucosal irritation and colonization

Back to Table of Contents

5. Clinical Presentation

Acute Viral Tonsillitis

Viral pharyngotonsillitis typically presents with gradual onset of sore throat accompanied by rhinorrhea, nasal congestion, cough, hoarseness, and low-grade fever. The tonsils appear erythematous and edematous but exudate is less common than in bacterial disease (though adenovirus can produce a striking exudative tonsillitis). Oral ulcers and vesicles suggest herpetic or coxsackievirus etiology. Infectious mononucleosis due to EBV produces the most severe viral tonsillitis: markedly enlarged, edematous, exudative tonsils (sometimes meeting in the midline — "kissing tonsils"), diffuse bilateral cervical lymphadenopathy, splenomegaly (in 50% of cases), hepatomegaly, and a characteristic peripheral blood smear showing >10% atypical lymphocytes. Airway obstruction can occur with very large EBV tonsils.

Acute Bacterial Tonsillitis (GAS)

GAS pharyngotonsillitis classically presents with abrupt onset of severe sore throat, odynophagia, fever >38.3°C (101°F), and marked tonsillar enlargement with erythema. The presence of tonsillar exudate (white or gray patches of purulent material on the tonsil surface), tender anterior cervical lymphadenopathy, and the absence of cough are the cardinal features distinguishing GAS from viral pharyngitis. Constitutional symptoms include headache, malaise, myalgia, and anorexia. In young children, GAS may present with abdominal pain, nausea, and vomiting rather than classic throat symptoms. When GAS secretes pyrogenic exotoxins, a diffuse scarlatiniform rash (fine, sandpaper-textured erythema sparing the face but creating a perioral pallor) and strawberry tongue develop, defining scarlet fever — a presentation of GAS pharyngitis rather than a separate disease.

Peritonsillar Abscess (PTA)

Peritonsillar abscess is the most common deep space neck infection and represents suppurative spread of tonsillitis into the peritonsillar space (between the tonsillar capsule and the superior constrictor muscle). It presents with progressive unilateral throat pain, a characteristic "hot potato voice" (muffled, potato-in-mouth speech quality from palatal and peritonsillar swelling), trismus (difficulty opening the mouth due to pterygoid muscle spasm), drooling, and uvular deviation away from the affected side. The affected tonsil is displaced medially and inferiorly, and the soft palate is bulging and erythematous. High fever and systemic toxicity are common.

Chronic and Recurrent Tonsillitis

Recurrent acute tonsillitis produces repeated episodes of sore throat with the features described above. Between episodes, patients may be entirely asymptomatic. Chronic tonsillitis manifests as persistent sore throat, halitosis, and tonsilloliths (white or yellow calcified debris lodged in the crypts, visible on examination). The tonsils may appear scarred and irregular without frank enlargement. Tonsillar hypertrophy — physical enlargement of the tonsils even without acute infection — can cause obstructive sleep apnea (OSA), snoring, dysphagia, and muffled voice, particularly in children. Grading of tonsillar size uses the Brodsky scale: Grade 1 (tonsils within the pillars), Grade 2 (tonsils extending to but not reaching the midline), Grade 3 (tonsils extending 50-75% toward the midline), Grade 4 (tonsils meeting or nearly meeting in the midline, "kissing tonsils").

Back to Table of Contents

6. Diagnosis

The Centor Criteria

The Centor score is the most widely used clinical decision tool to estimate the probability of GAS pharyngotonsillitis and guide diagnostic testing and empiric treatment. The original four Centor criteria are:

1. Tonsillar exudate — visible white or gray patches on the tonsil surface (1 point)
2. Tender anterior cervical lymphadenopathy — swollen, painful lymph nodes in the anterior cervical chain (1 point)
3. Fever history >38°C (100.4°F) — documented or reported fever (1 point)
4. Absence of cough — cough is a feature of viral (particularly adenoviral) pharyngitis and makes GAS less likely (1 point)

Score interpretation: 0-1 points — GAS probability <10%, no testing or antibiotics recommended; 2-3 points — GAS probability 15-35%, test with rapid antigen detection test (RADT) and treat if positive; 4 points — GAS probability 40-60%, consider empiric treatment or test first.

McIsaac Modification

The McIsaac score adds an age adjustment to improve specificity in adults: subtract 1 point for age ≥45 years, add 1 point for age 3-14 years. This modification reduces unnecessary antibiotic prescribing in low-risk adults and improves overall diagnostic accuracy across age groups. A modified score ≤1 has a negative predictive value of approximately 90-95% for GAS, making testing and treatment unnecessary.

Rapid Antigen Detection Test (RADT)

The RADT (rapid strep test) detects GAS cell wall carbohydrate antigen from a throat swab within 5-10 minutes at the point of care. Performance characteristics:

• Sensitivity: 70-90% (varies by test brand and operator technique)
• Specificity: 95-99% (a positive RADT is almost always a true positive)
• A positive RADT confirms GAS infection and warrants antibiotic treatment
• A negative RADT in children should be followed by a throat culture (sensitivity 90-95%) to exclude GAS, because the consequences of missed GAS (rheumatic fever) are more serious in children than adults. Most guidelines recommend backup culture for children but accept a negative RADT alone in adults, where ARF risk is very low.

Throat Culture

A throat swab culture on sheep blood agar remains the gold standard for GAS diagnosis, with sensitivity of 90-95% and specificity of 99%. Results require 24-48 hours to finalize. The swab must contact both tonsils and the posterior pharynx to maximize sensitivity. Culture also allows antimicrobial susceptibility testing, which is increasingly relevant given rising macrolide resistance in GAS.

Laboratory and Imaging Studies

• Complete blood count (CBC) — leukocytosis with neutrophilia supports bacterial infection; marked lymphocytosis with >10% atypical lymphocytes suggests EBV mononucleosis
• Monospot test (heterophile antibody test) — rapid test for EBV mononucleosis; sensitivity 85-90%, specificity ~99% in adolescents and adults; may be falsely negative in the first week of illness and in children under 5
• EBV-specific antibodies (VCA IgM/IgG, EA, EBNA) — confirmatory when monospot is negative but EBV mononucleosis is clinically suspected
• Anti-streptolysin O (ASO) titer — not useful for diagnosing acute tonsillitis (rises 3-5 weeks after infection) but confirms prior GAS infection when evaluating possible rheumatic fever or post-streptococcal glomerulonephritis
• CT scan of the neck — indicated when peritonsillar abscess or deep neck space infection is suspected; distinguishes cellulitis from a drainable abscess; demonstrates medial displacement of the tonsil and a hypodense collection with ring enhancement in PTA
• Ultrasound (intraoral or transcutaneous) — useful to differentiate peritonsillar abscess from cellulitis when CT is not immediately available

Back to Table of Contents

7. Treatment

Supportive Care (All Cases)

Symptomatic relief is the cornerstone of management for viral tonsillitis and an important adjunct in bacterial cases:

• Analgesics and antipyretics — ibuprofen (superior anti-inflammatory effect) or acetaminophen; ibuprofen provides faster and greater relief of sore throat pain in most comparative studies
• Adequate hydration — essential in febrile children; cold fluids and ice chips can soothe throat pain
• Salt water gargling — traditional remedy that provides mild symptomatic relief; no proven antibacterial effect
• Throat lozenges and sprays — benzocaine or dyclonine-containing anesthetics provide brief topical analgesia
• Corticosteroids — a single dose of dexamethasone 10 mg IM/PO (or oral prednisone 40-60 mg × 1-3 days) significantly accelerates symptomatic improvement in acute pharyngotonsillitis; most beneficial in severe exudative tonsillitis; does not increase complication rates when combined with antibiotics in GAS disease. Also the primary treatment for severe EBV tonsillar enlargement threatening the airway.

Antibiotic Therapy for GAS

Antibiotic treatment of confirmed or highly probable GAS pharyngotonsillitis achieves four important goals: shortening illness duration (by approximately 1-2 days), preventing suppurative complications (peritonsillar abscess, retropharyngeal abscess), reducing contagiousness (patients become non-infectious within 24 hours of starting antibiotics), and most critically, preventing acute rheumatic fever (requires eradication of GAS from the pharynx, which requires a full 10-day course of penicillin).

First-line regimens (per 2012 IDSA guidelines):

• Penicillin V (phenoxymethylpenicillin) — 500 mg orally twice daily × 10 days (adults and children ≥27 kg); children <27 kg: 250 mg twice daily × 10 days. GAS has never developed clinically significant resistance to penicillin — the drug of choice for over 70 years. The full 10-day course is essential; symptom improvement typically occurs within 3-4 days, but early discontinuation leads to treatment failure and relapse.
• Amoxicillin — 500 mg orally twice daily × 10 days (or 50 mg/kg once daily × 10 days in children; max 1000 mg/day). Equivalent efficacy to penicillin V; better taste in liquid formulation makes compliance easier in children; amoxicillin 875 mg twice daily is an alternative adult regimen. Avoid amoxicillin when EBV mononucleosis is possible — causes diffuse maculopapular rash in 80-90% of EBV-infected patients.
• Benzathine penicillin G (intramuscular) — a single IM injection of 600,000 units (children <27 kg) or 1,200,000 units (adults and children ≥27 kg); ensures complete treatment in patients unlikely to complete a 10-day oral course; painful injection is a drawback.

Penicillin allergy:

• Azithromycin — 500 mg on day 1, then 250 mg days 2-5 (5-day course); a convenient regimen but macrolide resistance in GAS is increasing (5-30% in the US; higher in some countries); susceptibility testing recommended when macrolides are used
• Clarithromycin — 250 mg twice daily × 10 days; similar macrolide resistance concerns as azithromycin
• Clindamycin — 300 mg three times daily × 10 days; effective against GAS including macrolide-resistant strains; preferred for documented penicillin allergy when macrolide resistance is a concern
• First-generation cephalosporins (cephalexin, cefadroxil) — appropriate when penicillin allergy is non-anaphylactic; cross-reactivity between penicillins and cephalosporins is <2% with modern cephalosporins

Peritonsillar Abscess Treatment

Peritonsillar abscess requires drainage plus antibiotic therapy:

• Needle aspiration — first-line; performed under local anesthesia at the point of maximal fluctuance (typically the superior pole); successful in 85-90% of cases; may need to be repeated once if insufficient drainage
• Incision and drainage (I&D) — more definitive when needle aspiration fails; provides larger drainage channel; preferred by many surgeons for recurrent PTA
• Quinsy tonsillectomy (tonsillectomy in the acute setting) — reserved for patients with multiple recurrences, immunocompromised patients, and those with diagnostic uncertainty; more technically challenging acutely but eliminates further recurrence
• Antibiotic therapy — IV penicillin plus metronidazole (for anaerobic coverage) during hospitalization, followed by oral amoxicillin-clavulanate to complete a 10-14 day course; clindamycin as an alternative providing both GAS and anaerobic coverage

Surgical Treatment: Tonsillectomy

Tonsillectomy remains one of the most common operations in the United States and globally. The decision to proceed is based on carefully defined indications balancing surgical benefit against operative risks.

Paradise criteria for recurrent tonsillitis (the evidence-based standard):

• 7 or more episodes in the preceding 1 year, OR
• 5 or more episodes per year for 2 consecutive years, OR
• 3 or more episodes per year for 3 consecutive years
• Each episode must be documented by a physician and must include one or more of: temperature ≥38.3°C, cervical lymphadenopathy, tonsillar exudate, or positive GAS culture/RADT

Additional indications for tonsillectomy:

• Obstructive sleep apnea due to tonsillar hypertrophy — the most common indication in children today; polysomnography-confirmed OSA with tonsillar hypertrophy is a strong indication; tonsillectomy and adenoidectomy (T&A) is curative in 70-90% of pediatric OSA cases
• Recurrent peritonsillar abscess — second episode or first episode in a high-risk patient
• Suspected tonsillar malignancy — unilateral tonsillar enlargement, particularly in adults with risk factors (tobacco, alcohol, HPV exposure)
• Chronic tonsillitis with significant quality-of-life impairment not responding to medical management

Surgical techniques include traditional cold-steel dissection, electrocautery, and newer modalities (coblation, laser, microdebrider). Intracapsular tonsillectomy (tonsillotomy) — partial removal leaving the tonsillar capsule intact — is gaining favor for OSA in children because it reduces post-operative pain and bleeding risk compared to total tonsillectomy, though it carries a small risk of tonsillar regrowth. Post-tonsillectomy hemorrhage is the most feared complication, occurring in 2-5% of patients (primary within 24 hours, secondary on days 5-10 when the eschar separates).

Back to Table of Contents

8. Complications

Suppurative (Infectious) Complications

Peritonsillar Abscess

Peritonsillar abscess (PTA) is the most common deep space infection of the head and neck, accounting for approximately 45,000 emergency department visits per year in the United States. PTA develops when tonsillitis spreads beyond the tonsillar capsule into the peritonsillar space, where pus accumulates between the superior constrictor muscle and the tonsil. It is a polymicrobial infection involving GAS together with anaerobes (Fusobacterium, Prevotella, Peptostreptococcus) that colonize the tonsillar crypts. The classic presentation — "hot potato" muffled voice, trismus, uvular deviation, and drooling — is distinct and usually diagnostic. Rare but serious complications of untreated PTA include spread to the retropharyngeal space, parapharyngeal space, or the deep spaces of the neck, potentially causing necrotizing fasciitis, mediastinitis, and life-threatening airway obstruction.

Retropharyngeal and Parapharyngeal Space Infections

More serious deep neck space infections can arise from direct extension of tonsillar or peritonsillar infection. Retropharyngeal abscess is most common in children under 6 (due to retropharyngeal lymph nodes that involute with age) and presents with stiff neck, drooling, and muffled cry. Ludwig's angina (cellulitis of the floor of the mouth) and descending necrotizing mediastinitis are life-threatening complications requiring emergent surgical drainage and aggressive IV antibiotics.

Lemierre's Syndrome

Lemierre's syndrome (postanginal septicemia) is a rare but potentially fatal complication, most commonly occurring in previously healthy adolescents and young adults. It is caused by Fusobacterium necrophorum spreading from the pharynx to the internal jugular vein, causing septic thrombophlebitis and subsequent septic emboli to the lungs, liver, joints, and other organs. Classic presentation: severe sore throat followed by high fever, rigors, and pleuritic chest pain within 1-3 weeks. Treatment requires prolonged IV antibiotics (metronidazole plus a beta-lactam) and often anticoagulation.

Acute Rheumatic Fever (ARF)

Acute rheumatic fever is the most important non-suppurative complication of GAS pharyngotonsillitis, occurring in 0.3-3% of untreated GAS pharyngitis cases (higher during epidemic strains). ARF is a delayed, immune-mediated, multi-system inflammatory disease that develops 2-4 weeks after GAS pharyngitis through antibody cross-reactivity with cardiac, joint, and neural tissues (molecular mimicry). The Jones criteria for ARF diagnosis require evidence of prior GAS infection plus either two major criteria or one major and two minor criteria. Major criteria include: carditis (the most serious manifestation — panCarditis with mitral and aortic valve damage in 40-60% of ARF cases), migratory polyarthritis (large joints, most common major criterion, 75% of cases), Sydenham's chorea (involuntary jerky movements, emotional lability), subcutaneous nodules, and erythema marginatum (skin rash). Repeated ARF episodes cause cumulative valve damage, ultimately leading to rheumatic heart disease (RHD) — the most common cause of acquired heart disease in people under 25 worldwide. A complete 10-day antibiotic course eliminates GAS and effectively prevents ARF even when started up to 9 days into the illness.

Post-Streptococcal Glomerulonephritis (PSGN)

PSGN is an immune complex-mediated nephritis caused by specific nephritogenic strains of GAS, occurring 1-3 weeks after pharyngeal GAS infection. It presents with hematuria (tea-colored urine), proteinuria, edema, and hypertension. Unlike ARF, antibiotic treatment of the precipitating GAS infection does not reliably prevent PSGN. In children, PSGN is usually self-limiting and resolves completely; in adults, chronic renal impairment may occur in a minority.

Obstructive Sleep Apnea (OSA)

Chronic tonsillar hypertrophy — particularly in children aged 2-8 who have physiologically large tonsils relative to airway size — is the leading cause of pediatric obstructive sleep apnea. OSA secondary to tonsillar hypertrophy causes fragmented sleep, nocturnal hypoxemia, and a range of neurobehavioral sequelae including inattention, hyperactivity, poor school performance, and behavioral problems that can closely mimic ADHD. Severe untreated pediatric OSA causes failure to thrive, pulmonary hypertension, and cor pulmonale in rare cases. Tonsillectomy with adenoidectomy (T&A) is curative for OSA in approximately 70-90% of children and is the most common indication for tonsillectomy in developed countries today.

Back to Table of Contents

9. Prognosis

The vast majority of tonsillitis episodes — both viral and bacterial — resolve completely without complications. Viral pharyngotonsillitis is self-limiting in 7-10 days in immunocompetent individuals. EBV mononucleosis typically resolves over 2-4 weeks, though fatigue may persist for several months in a minority of patients; contact sports should be avoided for 3-4 weeks after diagnosis to reduce the risk of splenic rupture. HSV primary tonsillitis resolves in 10-14 days and rarely requires antiviral therapy in healthy individuals.

GAS pharyngotonsillitis treated with a complete penicillin or amoxicillin course has an excellent prognosis: fever typically resolves within 24-48 hours of starting antibiotics, sore throat improves significantly within 48-72 hours, and the patient is typically non-infectious within 24 hours. Children should remain out of school until they have been on antibiotics for at least 24 hours and are afebrile. Treatment failure (persistent GAS carriage despite antibiotics) occurs in approximately 10-15% of cases; retreatment with amoxicillin-clavulanate or clindamycin (which have activity against beta-lactamase-producing oral flora that can inactivate penicillin) is usually successful.

The prognosis of recurrent tonsillitis depends on whether surgical intervention is pursued. Children meeting the Paradise criteria who undergo tonsillectomy experience a significant and durable reduction in throat infections: randomized trials show approximately 3 fewer sore throat episodes per year in the year following surgery compared to watchful waiting, with progressive convergence in subsequent years as children naturally outgrow the tendency to recurrent tonsillitis. Children with less severe recurrence (below Paradise threshold) show smaller benefit from tonsillectomy that may not justify surgical risk for most patients. The risk of post-tonsillectomy hemorrhage requiring operative intervention is approximately 1-3%, with higher rates in adults than children.

With proper antibiotic treatment, acute rheumatic fever is essentially preventable. Among patients with documented ARF, approximately 50-60% develop some degree of valvular disease over time without secondary prophylaxis; with long-term penicillin secondary prophylaxis (monthly benzathine penicillin G injections for 5-10 years or longer), progression to severe RHD is substantially reduced.

Back to Table of Contents

10. Prevention

Primary Prevention of GAS Pharyngitis

• Hand hygiene — regular hand washing with soap and water or alcohol-based hand rub; the most effective measure against respiratory pathogen transmission in community settings
• Respiratory etiquette — covering coughs and sneezes, disposing of tissues promptly
• Avoiding sharing utensils, cups, or personal items with infected individuals
• Prompt treatment of GAS infections — reduces household transmission; treated individuals are non-infectious within 24 hours
• No GAS vaccine currently available — development is ongoing; the antigenically variable M protein is the primary target, but the >200 GAS serotypes and concern about molecular mimicry have complicated vaccine development. Multivalent and conserved-antigen vaccines are in clinical trials.

Secondary Prevention of Rheumatic Fever

Patients who have had a documented episode of acute rheumatic fever are at markedly increased risk of recurrent ARF and progressive cardiac damage with subsequent GAS pharyngitis. Long-term secondary antibiotic prophylaxis is mandatory:

• Benzathine penicillin G 1,200,000 units IM every 3-4 weeks — most effective regimen; poor adherence to oral alternatives makes IM injection preferred in high-risk settings
• Duration: 10 years or until age 21 (whichever is longer) for ARF without carditis; 10 years or until age 40 for ARF with carditis but no persistent valve disease; lifelong prophylaxis for ARF with persistent rheumatic heart disease

Antibiotic Stewardship

Given that approximately 60% of pharyngotonsillitis is viral and does not require antibiotics, antibiotic stewardship is a critical aspect of tonsillitis management. Broad antibiotic prescribing for undifferentiated sore throat contributes to antimicrobial resistance, particularly macrolide resistance in GAS, and exposes patients to unnecessary side effects (diarrhea, allergic reactions, Clostridioides difficile colitis). The systematic application of Centor/McIsaac scoring and RADT testing — rather than empiric antibiotic prescribing for all sore throats — is the central strategy for appropriate antibiotic use.

Immune Support

• Vitamin C — adequate intake supports mucosal immunity and neutrophil function; deficiency impairs barrier defense
• Zinc — essential for lymphocyte proliferation and function; supplementation during illness may modestly reduce duration of upper respiratory infections
• Echinacea — modest evidence for reducing duration of viral upper respiratory tract infections; limited evidence specific to tonsillitis
• Adequate sleep and reduced stress — both significantly impact immune competence and susceptibility to pharyngeal infection

Back to Table of Contents

11. Key Research Papers

Clinical Practice Guidelines

1. Shulman ST et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86-102. — PMID: 22965026
2. Windfuhr JP et al. Clinical practice guideline: tonsillitis I. Diagnostics and nonsurgical management. Eur Arch Otorhinolaryngol. 2016;273(4):973-987. — PMID: 26755048
3. Mitchell RB et al. Clinical Practice Guideline: Tonsillectomy in Children (Update). Otolaryngol Head Neck Surg. 2019;160(1_suppl):S1-S42. — PMID: 30798778

Tonsillectomy and Surgical Outcomes

4. Paradise JL et al. Tonsillectomy and adenotonsillectomy for recurrent throat infection in moderately affected children. Pediatrics. 2002;110(1 Pt 1):7-15. — PMID: 12093941
5. Paradise JL et al. Efficacy of tonsillectomy for recurrent throat infection in severely affected children. Results of parallel randomized and nonrandomized clinical trials. N Engl J Med. 1984;310(11):674-683. — PMID: 6700642
6. Burton MJ, Glasziou PP, Chong LY, Venekamp RP. Tonsillectomy or adenotonsillectomy versus non-surgical treatment for chronic/recurrent acute tonsillitis. Cochrane Database Syst Rev. 2014;(11):CD001802. — PMID: 25407135

Streptococcal Pharyngitis and Rheumatic Fever

7. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685-694. — PMID: 16253886
8. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee. Circulation. 2009;119(11):1541-1551. — PMID: 19246689

Diagnostic Accuracy and Clinical Scores

9. McIsaac WJ, White D, Tannenbaum D, Low DE. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ. 1998;158(1):75-83. — PMID: 9475915
10. Cohen JF et al. Rapid antigen detection test for group A streptococcus in children with pharyngitis. Cochrane Database Syst Rev. 2016;7:CD010502. — PMID: 27374000

Treatment Efficacy

11. Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2021;12:CD000023. — PMID: 34827279
12. Hayward G et al. Corticosteroids as standalone or add-on treatment for sore throat. Cochrane Database Syst Rev. 2012;10:CD008268. — PMID: 23076943

PubMed Topic Searches

1. PubMed: Group A streptococcus pharyngitis treatment
2. PubMed: Tonsillectomy indications Paradise criteria
3. PubMed: Peritonsillar abscess drainage management
4. PubMed: Acute rheumatic fever streptococcal prevention
5. PubMed: Centor score streptococcal pharyngitis diagnosis
6. PubMed: Tonsillitis pediatric sleep apnea tonsillectomy
7. PubMed: Rapid antigen detection strep throat accuracy
8. PubMed: Fusobacterium necrophorum Lemierre syndrome
9. PubMed: EBV infectious mononucleosis tonsillitis
10. PubMed: Amoxicillin penicillin streptococcal pharyngitis 10 days

Back to Table of Contents

Connections

• Sinusitis
• Hearing Loss
• Vertigo & Ménière's Disease
• Strep Throat
• Epstein-Barr Virus
• Zinc
• Vitamin C
• Echinacea
• All Conditions
• ENT Conditions

Back to Table of Contents

Featured Videos